Global Molecular Diagnostics Cancer Oncology Market to 2023: New Diagnostics Create New Markets, New Roles for Diagnostics, Longevity and Outcomes, Expanding the Pharmaceutical Toolbox

News provided by

Oct 07, 2020, 15:30 ET

DUBLIN, Oct. 7, 2020 /PRNewswire/ -- The "Molecular Diagnostics Cancer Oncology Global Market Size, Strategy and Forecasts - 2019 to 2023" report has been added to ResearchAndMarkets.com's offering.

A market that just keeps on growing. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge. A range of dynamic trends are pushing market growth and company valuations.

Some of these include:

Personalized medicine
Pharmacogenomics
Liquid biopsy
Emergence of new economies with large markets
Greater understanding of the role of genetic material in Disease and Health

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

In addition customization work, breakouts for particular segments, assistance and support is included free of charge with every report.

The report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2018 United States Medicare Fee Payment Schedules to help understand test pricing in detail. See lists of all current FDA Approved Molecular Diagnostic Tests. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.

Based on extensive primary and secondary research the testing volume data is broken down into price and volumes allowing researchers and investors to quickly create informed and reasonable forecasts of demand. Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Key Topics Covered:

1. Introduction and Market Definition
1.1 What is Molecular Diagnostics
1.2 The Diagnostics Revolution
1.3 Market Definition
1.3.1 Revenue Market Size
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and laboratory Testing - Perspective
1.5.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview
2.1 Market Participants
2.2 Market Segments
2.2.1 Traditional Market Segmentation
2.2.2 Laboratory Focus and Segmentation
2.3 Industry Structure
2.3.1 Hospital Testing Share
2.3.2 Economies of Scale
2.3.3 Physician Office Labs
2.3.4 Physicians and POCT
2.4 Profiles of Key MDx Companies

10X Genomics
Abbott Laboratories
Adaptive Biotechnologies
Aethlon Medical
Agena Bioscience
Angle plc
Apocell
ARUP Laboratories
Beckman Coulter
Becton Dickinson
Bioarray Genetics
BioCartis
Biocept
Biodesix Inc
BioFluidica
BioGenex
bioMrieux
Bio-Rad
Bio-Techne
Bristol-Myers Squibb
Cancer Genetics
Caris Molecular Diagnostics
CellMax Life
Charles River
Chronix Biomedical
Circulogene
Clearbridge BioMedics
Clinical Genomics
Cynvenio
Cytolumina Technologies Corp
CytoTrack
Dako (Agilent)
Diagenode Diagnostics
Diagnologix LLC
Epic Sciences
Exosome Diagnostics
Fluidigm Corp
Fluxion Biosciences
Foundation Medicine
Freenome
Genomic Health
GenomOncology
GRAIL
Guardant Health
HalioDx
Horizon Discovery
HTG Molecular Diagnostics
iCellate
Illumina
Incell Dx
Inivata
Integrated Diagnostics
Invivoscribe
Leica Biosystems
Luminex
MDx Health
Merck & Co., Inc
MIODx
Molecular MD
MRM Proteomics Inc.
Myriad Genetics/Myriad RBM
Nanostring
Natera
Neogenomics
New Oncology
Oncocyte
Ortho Clinical Diagnostics
Perkin Elmer
Personal Genome Diagnostics
Pfizer
Promega
Protagen Diagnostics
Qiagen
Quanterix
Rarecells SAS
Roche Diagnostics
Siemens
Silicon Biosystems
SkylineDx
SRI International
Sysmex
Thermo Fisher
Trovagene
Vortex Biosciences

3. Market Trends
3.1 Factors Driving Growth
3.1.1 New Diagnostics Create New Markets
3.1.2 New Roles for Diagnostics
3.1.3 Longevity and Outcomes
3.1.3 Expanding the Pharmaceutical Toolbox
3.1.4 Regulatory Retreat
3.2 Factors Limiting Growth
3.2.1 Falling Prices
3.2.2 Lower Costs
3.2.3 Testing as a Controllable Cost
3.2.4 Wellness has a Downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing
3.4.2 Shifting Role of Diagnostics
3.4.3 Multiplexing and Foundation One
3.4.4 Pharmacogenomics Technology
3.4.5 Whole Genome Sequencing
3.4.6 Gene Editing and Gene Therapy

4. Molecular Diagnostics Recent Developments

Recent Developments - Importance and How to Use This Section
Importance of These Developments
How to Use This Section
Icon Acquires MolecularMD
Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca
Adaptive Biotechnologies to Leverage Genentech, Microsoft Deals to Advance Immune Profiling Business
Illumina to Launch New NovaSeq Chip, iSeq Kit; Grow Oncology and Reproductive Health Business
UgenTec, MDxHealth Partner To Develop AI Software for Prostate Cancer Tests
Guardant Health, Core Diagnostics to Offer Liquid Biopsy in India
Invitae Q3 Revenues More Than Double
Illumina to Acquire Pacific Biosciences
Lung Cancer Panel From PlexBio Receives CE Mark
Thermo Fisher Scientific Gets CE-IVD Mark for Oncomine Dx
Merck KGaA, ArcherDx Partner to Develop CDx for Downstream Therapeutic
Foundation Medicine and Merck to Develop Diagnostic Tests for Keytruda
Cancer Genetics and NovellusDx to Merge
ApoCell Expands Immuno-Oncology Biomarker Services
MRM Proteomics Inc and Exactis Innovation Partner
Agilent Companion Diagnostic Gains FDA Approval in Urothelial Carcinoma
Fluidigm Partners with GenomOncology to Provide Immuno-Oncology Solution
MolecularMD Launches Validated Tumor Mutation Burden Assay
Minomic Secures Key Patent in the United States and China
Biocartis and Wondfo Announce Joint Venture
Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics
Biodesix Acquires Integrated Diagnostics
Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx
Bio-Techne to Acquire Exosome Dx for Up to $575m
GRAIL Announces Data on Detection of Early-Stage Lung Cancers
CellMax Life, IncellDx Partner to Develop Circulating Tumor Cell Tests
Quest to Offer Thermo Fisher's Oncomine Dx Target Test
Angle, Abbott Ink Deal for Use of FISH With Harvested CTCs
Foundation Medicine to Profile Samples for European Cancer Network
GRAIL Details Plans for Early Cancer Detection Trials, Products
Avalon GloboCare, Da An Gene Collaborate on Liquid Biopsy Diagnostics
OncoDNA Inks Russian Distribution Deal With Genext
Biocept Prices $15M Public Offering

5. The Global Market for MDx Cancer
5.1 MDx Cancer - Global Market Overview by Country

6. Global MDx Cancer Markets - By Type of Cancer
6.1 Global Market by Cancer Type - Overview
6.2 MDx Breast Cancer
6.3 MDx Colorectal Cancer
6.4 MDx Cervical Cancer
6.5 MDx Lung Cancer
6.6 MDx Precancer
6.7 MDx Prostate Cancer
6.8 MDx Melanoma
6.9 MDx Blood Cancer
6.10 MDx Other Cancer

7. Cancer Treatment and Trials
7.1 FDA Cancer Drug Approvals by Year
7.2 Clinical Trials Started 2010 to 2016
7.3 Prevalence of Cancer Treatments - 2015

8. Appendices
I. United States Medicare System: January 2019 Clinical Laboratory Fees Schedule
II. FDA Approved Human Genetic Tests
III. FDA Approved Microbial Tests
III. FDA Approved Pharmacogenomics Tests

For more information about this report visit https://www.researchandmarkets.com/r/wtq27v

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets